A Phase 2, Randomized, Double-blind, Sham-procedure Controlled Study to Assess the Safety and Tolerability and Explore the Efficacy of ISIS 396443 (BIIB058) Administered Intrathecally in Subjects With Spinal Muscular Atrophy Who Are Not Eligible to Participate in the Clinical Studies ISIS 396443-CS3B or ISIS 396443-CS4
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMBRACE
- Sponsors Biogen
- 05 Oct 2017 According to a Biogen media release, interim data were presented at the 22nd International Annual Congress of the World Muscle Society
- 24 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Apr 2019.
- 23 Dec 2016 Planned End Date changed from 1 Jan 2018 to 1 Apr 2019.